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Introduction {#bjs561-sec-0005}
============

Since its introduction by Toth and Lappert[1](#bjs561-bib-0001){ref-type="ref"}, rates of skin‐sparing mastectomy (SSM) and immediate breast reconstruction have been increasing[2](#bjs561-bib-0002){ref-type="ref"}. Both SSM and nipple‐sparing mastectomy preserve the native skin envelope and inframammary fold of the breast, which can be used to facilitate immediate reconstructive procedures. Surgeons are able to achieve superior aesthetic results compared with those of conventional mastectomy or delayed reconstruction, as well as offer both therapeutic and reconstructive procedures in one sitting. These advantages lead to higher levels of patient satisfaction, psychological outcomes and cost‐effectiveness[3](#bjs561-bib-0003){ref-type="ref"}.

Native mastectomy skin flap necrosis is a common complication when using skin‐sparing techniques. Reported rates are as high as 30 per cent[4](#bjs561-bib-0004){ref-type="ref"}. The challenge lies in complete removal of all breast tissue to ensure oncological safety, while leaving sufficient skin flap thickness to maintain skin viability[5](#bjs561-bib-0005){ref-type="ref"}. The superficial plane of dissection between the subcutaneous fat and breast tissue has been found to be indistinct under microscopic examination in almost half of patients[6](#bjs561-bib-0006){ref-type="ref"}, making it technically difficult, especially with the more limited field of view compared with that of conventional mastectomy. Immediate breast reconstruction is also associated with a significantly higher rate of complications (up to 50 per cent) compared with delayed procedures (up to 36 per cent)[7](#bjs561-bib-0007){ref-type="ref"}.

Other factors identified to pose a greater risk of mastectomy flap necrosis include patient‐related factors such as smoking[8](#bjs561-bib-0008){ref-type="ref"} [9](#bjs561-bib-0009){ref-type="ref"}, diabetes mellitus[10](#bjs561-bib-0010){ref-type="ref"} [11](#bjs561-bib-0011){ref-type="ref"}, high BMI[10](#bjs561-bib-0010){ref-type="ref"}, [11](#bjs561-bib-0011){ref-type="ref"}, [12](#bjs561-bib-0012){ref-type="ref"}, high mastectomy specimen weight[10](#bjs561-bib-0010){ref-type="ref"} [11](#bjs561-bib-0011){ref-type="ref"}, [13](#bjs561-bib-0013){ref-type="ref"}, and previous exposure to radiotherapy[12](#bjs561-bib-0012){ref-type="ref"} [14](#bjs561-bib-0014){ref-type="ref"}. Intraoperative factors such as tumescent mastectomy technique[9](#bjs561-bib-0009){ref-type="ref"} [15](#bjs561-bib-0015){ref-type="ref"} and Wise‐pattern mastectomy incision[13](#bjs561-bib-0013){ref-type="ref"} [16](#bjs561-bib-0016){ref-type="ref"} have also been associated with a higher rate of mastectomy flap necrosis[17](#bjs561-bib-0017){ref-type="ref"}.

Traditionally, mastectomy flap viability has been assessed clinically in the intraoperative setting[18](#bjs561-bib-0018){ref-type="ref"}. Subjective parameters such as skin colour, capillary refill time and dermal bleeding from skin edges are used to guide resection of non‐viable tissue. Over‐resection of potentially unviable tissue may be the safest option, but this may limit reconstructive options and compromise aesthetic outcomes[12](#bjs561-bib-0012){ref-type="ref"}. Rates of necrosis reported using this approach are approximately 10--15 per cent[19](#bjs561-bib-0019){ref-type="ref"}, with a specificity of 10--30 per cent[20](#bjs561-bib-0020){ref-type="ref"}.

Depending on the severity of skin flap ischaemia, the patient may develop superficial epidermolysis to full‐thickness necrosis[21](#bjs561-bib-0021){ref-type="ref"}. Management can vary between dressing care in an outpatient setting, or more significant consequences such as surgical debridement, additional reconstruction and exposure of the breast prosthesis requiring removal. Planned oncological therapies may be delayed and the patient\'s quality of life affected[10](#bjs561-bib-0010){ref-type="ref"}. Inadequate perfusion can also contribute to more generic complications such as delayed wound healing and infection[22](#bjs561-bib-0022){ref-type="ref"}. Finding a means of objectively assessing mastectomy flap perfusion accurately and cost‐effectively is desirable.

Fluorescence angiography techniques have been used to great effect by disciplines such as ophthalmology and other surgical specialties[23](#bjs561-bib-0023){ref-type="ref"}. They involve the injection of intravenous dye such as fluorescein or indocyanine green (ICG), which emits infrared energy in conjunction with use of a light source. By enabling real‐time assessment of tissue perfusion, a potentially more objective measure of viability can aid more accurate prediction of skin flap survival and help reduce rates of necrosis. Current applications of fluorescence angiography techniques in plastic surgery include sentinel lymph node biopsy, pedicled and free flap reconstructions as well as mastectomy skin flaps[24](#bjs561-bib-0024){ref-type="ref"}.

Previous reviews[24](#bjs561-bib-0024){ref-type="ref"}, [25](#bjs561-bib-0025){ref-type="ref"}, [26](#bjs561-bib-0026){ref-type="ref"}, [27](#bjs561-bib-0027){ref-type="ref"} have considered use of fluorescence angiography techniques in a variety of clinical applications without focusing on mastectomy flap viability. The aim of this systematic review was to identify all intraoperative techniques for assessment of mastectomy flap viability in patients undergoing SSM or nipple‐sparing mastectomy and immediate reconstruction with prosthesis or autologous tissue, and to compare outcomes with clinical judgement.

Methods {#bjs561-sec-0006}
=======

Search strategy {#bjs561-sec-0007}
---------------

A literature review of MEDLINE (1946--2017) and Embase (1947--2017) databases was conducted using keywords in the English language combined with Boolean logical operators. Search strategies are available in full in *Tables*  [S1](#bjs561-supitem-0001){ref-type="supplementary-material"} and [S2](#bjs561-supitem-0001){ref-type="supplementary-material"} (supporting information). No further supplementary searches were undertaken. The primary outcomes were accuracy of each modality in predicting necrosis, and rates of mastectomy flap necrosis and reoperation. Secondary outcomes included cost analysis and complications directly associated with assessment modality.

Study selection {#bjs561-sec-0008}
---------------

Duplicate articles were removed and all abstracts written in the English language were screened for full‐text review by two authors independently. This included articles published in languages other than English. Inclusion criteria were all original comparative studies using intraoperative techniques to determine mastectomy flap perfusion in patients undergoing immediate breast reconstruction after SSM or nipple‐sparing mastectomy. Exclusion criteria were studies with alternative populations, interventions or outcomes of interest, such as use of intraoperative modalities to assess sentinel lymph node biopsies or autologous perforator flap perfusion.

Data extraction {#bjs561-sec-0009}
---------------

Data were extracted by two independent reviewers, including: authors; year of publication; study design; number of patients; number of breasts; type of mastectomy; type of reconstruction; duration of follow‐up; technique for mastectomy flap assessment; rate of necrosis; rate of reoperation; sensitivity, specificity and predictive values of each technique; cost analysis; and complications relating to technique. Sensitivity, specificity and predictive values were calculated from the data presented when not specified. Discrepancies were checked and resolved by consensus.

Assessment of study quality {#bjs561-sec-0010}
---------------------------

All studies were assigned a level of evidence (LOE) adapted from the Oxford Centre for Evidence‐Based Medicine (<http://www.cebm.net/index.aspx?o=1025>) based on methodology and study design. The assigned levels were: LOE 1, RCT; LOE 2, cohort study; LOE 3, case--control study; LOE 4, case series; and LOE 5, expert opinion or case report.

Results {#bjs561-sec-0011}
=======

Study identification {#bjs561-sec-0012}
--------------------

A total of 1886 abstracts were retrieved from searches (*Fig*. [1](#bjs561-fig-0001){ref-type="fig"}). After detailed examination of 30 full‐text articles, 18 studies[7](#bjs561-bib-0007){ref-type="ref"} [19](#bjs561-bib-0019){ref-type="ref"}, [20](#bjs561-bib-0020){ref-type="ref"} [28](#bjs561-bib-0028){ref-type="ref"}, [29](#bjs561-bib-0029){ref-type="ref"}, [30](#bjs561-bib-0030){ref-type="ref"}, [31](#bjs561-bib-0031){ref-type="ref"}, [32](#bjs561-bib-0032){ref-type="ref"}, [33](#bjs561-bib-0033){ref-type="ref"}, [34](#bjs561-bib-0034){ref-type="ref"}, [35](#bjs561-bib-0035){ref-type="ref"}, [36](#bjs561-bib-0036){ref-type="ref"}, [37](#bjs561-bib-0037){ref-type="ref"}, [38](#bjs561-bib-0038){ref-type="ref"}, [39](#bjs561-bib-0039){ref-type="ref"}, [40](#bjs561-bib-0040){ref-type="ref"}, [41](#bjs561-bib-0041){ref-type="ref"}, [42](#bjs561-bib-0042){ref-type="ref"}, including 2077 patients, were included in this review.

![PRISMA diagram showing selection of articles for review](BJS5-2-175-g001){#bjs561-fig-0001}

Study characteristics {#bjs561-sec-0013}
---------------------

Designs were prospective cohort study (8), retrospective case series (4), prospective case series (3), retrospective case--control study (1), prospective pilot trial (1) and cost analysis study (1). Three intraoperative modalities for determining mastectomy flap perfusion were identified: indocyanine green angiography (ICGA) (16 studies), fluorescein dye angiography (FA) (3) and optical diffusion imaging spectroscopy (ODIS) (1).

Study design and level of evidence {#bjs561-sec-0014}
----------------------------------

Two different approaches were taken in the evaluation of mastectomy flap viability assessment using intraoperative techniques. One was to compare rates of mastectomy necrosis and other complications, such as reoperation rates, and clinical outcomes between the techniques used (Table [1](#bjs561-tbl-0001){ref-type="table"}). Seven case series[7](#bjs561-bib-0007){ref-type="ref"} [28](#bjs561-bib-0028){ref-type="ref"}, [29](#bjs561-bib-0029){ref-type="ref"}, [30](#bjs561-bib-0030){ref-type="ref"}, [31](#bjs561-bib-0031){ref-type="ref"}, [32](#bjs561-bib-0032){ref-type="ref"} [34](#bjs561-bib-0034){ref-type="ref"} and one cohort study[33](#bjs561-bib-0033){ref-type="ref"} used this approach. The alternative approach in seven prospective cohort studies[19](#bjs561-bib-0019){ref-type="ref"} [20](#bjs561-bib-0020){ref-type="ref"}, [35](#bjs561-bib-0035){ref-type="ref"}, [36](#bjs561-bib-0036){ref-type="ref"}, [37](#bjs561-bib-0037){ref-type="ref"}, [38](#bjs561-bib-0038){ref-type="ref"}, [39](#bjs561-bib-0039){ref-type="ref"} was to evaluate flap perfusion using the intraoperative modalities and to record the predicted areas of necrosis using photographic documentation or video recording. Tissue resection, however, was done according to the surgeon\'s clinical judgement. The clinical outcome of the mastectomy flap was then compared with previously predicted outcomes of the assessment technique to calculate sensitivity, specificity and predictive values (Table [2](#bjs561-tbl-0002){ref-type="table"}). One retrospective case--control study[40](#bjs561-bib-0040){ref-type="ref"} and one case series[41](#bjs561-bib-0041){ref-type="ref"} were designed to define numerical parameters corresponding to perfusion when using intraoperative techniques. Two studies[30](#bjs561-bib-0030){ref-type="ref"} [42](#bjs561-bib-0042){ref-type="ref"} performed retrospective cost analysis for the use of ICGA (including a secondary cost analysis in a case series[30](#bjs561-bib-0030){ref-type="ref"}).

###### 

Summary of all studies reporting rates of mastectomy flap necrosis and reoperation using intraoperative techniques

  Reference                                                           Study design                 LOE                No. of breasts                            Type of reconstruction                                 Follow‐up                      Technique    Overall complications (%)   Mastectomy flap necrosis (%)   Reoperation (%)[\*](#bjs561-note-0002){ref-type="fn"}  
  ------------------------------------------------------------------- --------------------------- ----- ------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------ --------------------------- ------------------------------ ------------------------------------------------------- ---------
  Rao et al. [34](#bjs561-bib-0034){ref-type="ref"}                   Prospective pilot study       4                       5                                             0                                                5                           4 weeks               ODIS                           --                                         20                             20 (M)
  Jones et al. [28](#bjs561-bib-0028){ref-type="ref"}                 Prospective case series       4                       57                                            31                                               26                             --                 ICGA                           --                                          6                              2 (M)
  Komorowska‐Timek and Gurtner[7](#bjs561-bib-0007){ref-type="ref"}   Prospective case series       4                       24                                            8                                                16                             --                 ICGA                           4                                           4                              4 (M)
  206                                                                 --                           --                       --                                            CJ                                              15·1                            --                  --                                                                                                     
  Sood and Glat[29](#bjs561-bib-0029){ref-type="ref"}                 Retrospective case series     4                       62                                            0                                                62                             --                 ICGA                           18                                         10                              7 (M)
  80                                                                  --                           --                       --                                            CJ                                               37                             17                13 (M)                                                                                                   
  Duggal et al. [30](#bjs561-bib-0030){ref-type="ref"}                Retrospective case series     4    184[†](#bjs561-note-0003){ref-type="fn"}   129 (91[‡](#bjs561-note-0004){ref-type="fn"} )   149 (91[‡](#bjs561-note-0004){ref-type="fn"} )   8·7 months             ICGA                          42·7                                       13·0                            5·9 (O)
  184[†](#bjs561-note-0003){ref-type="fn"}                            24·7 months                  CJ                      46·7                                          23·4                                           14·1 (O)                                                                                                                                                     
  Harless and Jacobson[31](#bjs561-bib-0031){ref-type="ref"}          Retrospective case series     4                      213                                            0                                               213                         4·6 months             ICGA                          6·6                                         0·9                            0·9 (M)
  254                                                                 0                            254                 16·9 months                                        CJ                                              13·8                           6·7                4·7 (M)                                                                                                  
  Diep et al. [32](#bjs561-bib-0032){ref-type="ref"}                  Retrospective case series     4                       77                                            0                                                77                          90 days               ICGA                           51                                7 (moderate--severe)                     5 (M)
  68                                                                  0                            68                       CJ                                            43                                          19 (severe)                       19 (M)                                                                                                                       
  Rinker[33](#bjs561-bib-0033){ref-type="ref"}                        Prospective cohort study      2                       35                                            14                                               21                         10 months              ICGA                           --                                         14                             15 (O)
  34                                                                  10                           24                       FA                                            --                                               3                            0 (O)                                                                                                                        
  30                                                                  11                           19                       CJ                                            --                                               27                           20 (O)                                                                                                                       

Reoperation rates are shown for overall complications (O) and mastectomy flap necrosis (M).

Number of patients.

Combined autologous/prosthetic reconstructions in a total of 91 breasts. LOE, level of evidence; ODIS, optical diffusion infrared spectroscopy; ICGA, indocyanine green angiography; CJ, clinical judgement; FA, fluorescein dye angiography.

###### 

Summary of all studies reporting sensitivity, specificity, positive and negative predictive values using intraoperative techniques

  Reference                                                 No. of breasts                               Type of reconstruction                                                              Follow‐up (months)                                  Technique   Mastectomy flap necrosis (%)   Reoperation (%)   Sensitivity (%)                 Specificity (%)                 PPV (%)   NPV (%)
  -------------------------------------------------------- ---------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ----------- ------------------------------ ----------------- ----------------- --------------------------------------------- --------- ---------
  Losken et al. [39](#bjs561-bib-0039){ref-type="ref"}            50                          31 (19[\*](#bjs561-note-0006){ref-type="fn"})                                     0 (19[\*](#bjs561-note-0006){ref-type="fn"})                        --                    FA                                        75                              71                          96        25
  Newman et al. [35](#bjs561-bib-0035){ref-type="ref"}            20                                                1                                                                                19                                             --                   ICGA                                       100                             91                          90        10
  CJ                                                              45                                               35                                                                                                                                                                                                                                                                  
  Murray et al. [36](#bjs561-bib-0036){ref-type="ref"}           227                                               --                                                                                --                                             --                   ICGA                                       --                              --                          100       --
  CJ                                                             4·4                                               1·8                                                                                                                                                                                                                                                                 
  Moyer and Losken[20](#bjs561-bib-0020){ref-type="ref"}          15         2[†](#bjs561-note-0007){ref-type="fn"} (6[‡](#bjs561-note-0008){ref-type="fn"})   6[†](#bjs561-note-0007){ref-type="fn"} (6[‡](#bjs561-note-0008){ref-type="fn"})      --                   ICGA                                       85                              88                          88        16
  118[†](#bjs561-note-0007){ref-type="fn"}                        --                                               --                                                                                CJ                                             14                    --                                                                                                           
  Phillips et al. [37](#bjs561-bib-0037){ref-type="ref"}          51                                                0                                                                                51                                            13·3                  ICGA                                       100         70--90[¶](#bjs561-note-0009){ref-type="fn"}            
  FA                                                                                                               90                                                                                30                                             48                    82                                                                                                           
  CJ                                                              41                                               10                                                                                                                                                                                                                                                                  
  Munabi et al. [19](#bjs561-bib-0019){ref-type="ref"}            62                                               12                                                                                50                                             8·8                  ICGA                                     38--100       72--83[¶](#bjs561-note-0009){ref-type="fn"}     44        98
  CJ                                                              13                                                0                                                                                                                                                                                                                                                                  
  Mattison et al. [38](#bjs561-bib-0038){ref-type="ref"}          55                                                0                                                                                55                                             --                   ICGA                                       100                             68                          35        100
                                                                  CJ                                               15                                                                                15                                                                                                                                                                                

All are prospective comparative cohort studies, with level of evidence 2.

Combined autologous/prosthetic reconstructions in a total of 19 breasts.

Number of patients.

Combined autologous/prosthetic reconstructions in a total of six patients.

Range of values for different absolute perfusion cut‐off values for mastectomy flap necrosis. PPV, positive predictive value; NPV, negative predictive value; FA, fluorescein dye angiography; ICGA, indocyanine green angiography; CJ, clinical judgement.

Mastectomy flap necrosis and reoperation {#bjs561-sec-0015}
----------------------------------------

Mastectomy flap necrosis rates were compared with clinical judgement in seven[7](#bjs561-bib-0007){ref-type="ref"} [28](#bjs561-bib-0028){ref-type="ref"}, [29](#bjs561-bib-0029){ref-type="ref"}, [30](#bjs561-bib-0030){ref-type="ref"}, [31](#bjs561-bib-0031){ref-type="ref"}, [32](#bjs561-bib-0032){ref-type="ref"}, [33](#bjs561-bib-0033){ref-type="ref"} studies using ICGA, one study using FA[33](#bjs561-bib-0033){ref-type="ref"} and one pilot study using ODIS[34](#bjs561-bib-0034){ref-type="ref"}. Use of ICGA in 652 and FA in 34 breasts resulted in a decrease in mean mastectomy flap necrosis compared with clinical judgement in 1964 breasts (7·9 and 3 compared with 19·4 per cent) (Table [3](#bjs561-tbl-0003){ref-type="table"}). Use of ODIS in five patients resulted in a mastectomy flap necrosis rate of 20 per cent[34](#bjs561-bib-0034){ref-type="ref"}. Studies varied in their classification of skin necrosis; some did not offer a definition, whereas others[30](#bjs561-bib-0030){ref-type="ref"} [32](#bjs561-bib-0032){ref-type="ref"}, [35](#bjs561-bib-0035){ref-type="ref"} used a scoring system such as mild, moderate or severe, with a description of what was meant by these terms.

###### 

Summary of all studies reporting mastectomy flap necrosis and reoperation rates using clinical judgement compared with indocyanine green angiography and fluorescein dye angiography

  Reference                                                            Clinical judgement   ICGA    FA                               
  ------------------------------------------------------------------- -------------------- ------ ------ ----- ------ ----- ---- --- ---
  Rinker[33](#bjs561-bib-0033){ref-type="ref"}                                 30            27     20    35     14    15    34   3   0
  Diep et al. [32](#bjs561-bib-0032){ref-type="ref"}                           68            19     19    77     7      5            
  Mattison et al. [38](#bjs561-bib-0038){ref-type="ref"}                       55            15     15                               
  Harless and Jacobson[31](#bjs561-bib-0031){ref-type="ref"}                  254           6·7    4·7    213   0·9    0·9           
  Duggal et al. [30](#bjs561-bib-0030){ref-type="ref"}                        186           23·4   14·1   184   13·0   5·9           
  Kanuri et al. [42](#bjs561-bib-0042){ref-type="ref"}                        710           11·1   11·1                              
  Munabi et al. [19](#bjs561-bib-0019){ref-type="ref"}                         62            13     0                                
  Sood and Glat[29](#bjs561-bib-0029){ref-type="ref"}                          80            17     13    62     10     7            
  Murray et al. [36](#bjs561-bib-0036){ref-type="ref"}                        227           4·4    1·8                               
  Phillips et al. [37](#bjs561-bib-0037){ref-type="ref"}                       51            41     10                               
  Moyer and Losken[20](#bjs561-bib-0020){ref-type="ref"}                       15            14     --                               
  Komorowska‐Timek and Gurtner[7](#bjs561-bib-0007){ref-type="ref"}           206            15     --    24     4      4            
  Newman et al. [35](#bjs561-bib-0035){ref-type="ref"}                         20            45     35                               
  Jones et al. [28](#bjs561-bib-0028){ref-type="ref"}                                        57     6      2                         
  Total no. of breasts                                                        1964                 652           34                  
  Mean % rate[\*](#bjs561-note-0101){ref-type="fn"}                                         19·4   12·9         7·9    5·5        3   0

Mean % rate was calculated by dividing the sum of % rates (to one decimal place) by the total number of studies.

ICGA, indocyanine green angiography; FA, fluorescein dye angiography.

Use of ICGA and FA led to a decrease in mean reoperation rate compared with clinical judgement (5·5 and 0 compared with 12·9 per cent) (Table [3](#bjs561-tbl-0003){ref-type="table"}). The use of ODIS was associated with a reoperation rate of 20 per cent[34](#bjs561-bib-0034){ref-type="ref"}. Rate of reoperation owing to direct causes of mastectomy flap necrosis was extracted when possible, but in cases of ambiguity reoperation for overall complications was used to calculate the mean rate (Table [2](#bjs561-tbl-0002){ref-type="table"}).

Predictive accuracy {#bjs561-sec-0016}
-------------------

The sensitivity and specificity were the highest for ICGA in five studies[19](#bjs561-bib-0019){ref-type="ref"} [20](#bjs561-bib-0020){ref-type="ref"}, [35](#bjs561-bib-0035){ref-type="ref"} [37](#bjs561-bib-0037){ref-type="ref"}, [38](#bjs561-bib-0038){ref-type="ref"}, ranging from 38 to 100 per cent and 68 to 91 per cent respectively. Two studies[37](#bjs561-bib-0037){ref-type="ref"} [39](#bjs561-bib-0039){ref-type="ref"} using FA reported a sensitivity of 75--90 per cent and specificity of 30--71 per cent. Both ICGA and FA overpredicted necrosis; one study[37](#bjs561-bib-0037){ref-type="ref"} reported that the overpredicted surface area was 6·57 cm^2^ (72 per cent) for ICGA and 18·86 cm^2^ (88 per cent) for FA.

It is notable that in both the studies using FA, any ambiguity in fluorescence was classified as non‐viable, and no effort was made to delineate between intermediate mottled appearances, which may explain the high rate of overprediction. This may also account for the findings of Rinker[33](#bjs561-bib-0033){ref-type="ref"}, who compared rates of mastectomy flap necrosis using all three modalities (clinical judgement, ICGA and FA) and reported a necrosis rate of 3 per cent and reoperation rate of 0 per cent with use of FA, which was the lowest of all techniques (Table [1](#bjs561-tbl-0001){ref-type="table"}). If all tissues with a mottled appearance were excised as described in the former two studies[37](#bjs561-bib-0037){ref-type="ref"} [39](#bjs561-bib-0039){ref-type="ref"}, a low necrosis rate is to be expected owing to over‐resection of potentially viable tissue. Indeed, the mean area of resection was larger when FA was used than with use of ICGA (6·2 versus 5·4 cm^2^ respectively), although the difference was not statistically significant[33](#bjs561-bib-0033){ref-type="ref"}. In a series of 50 consecutive SSMs with autologous reconstruction[39](#bjs561-bib-0039){ref-type="ref"}, a recommendation was therefore made to consider additional variables related to flap survival, such as surface area, previous irradiation and location of non‐fluorescence, when deciding resection margins.

Studies involving ICGA varied with respect to the device and software analysis used. Previously, only qualitative information was available through the SPY™ System software (Novadaq, Toronto, Ontario, Canada), which rendered grey‐scale images that required subjective interpretation by the surgeon similar to FA. This was used in two studies. Newman and colleagues[35](#bjs561-bib-0035){ref-type="ref"} reported a 95 per cent correlation between intraoperative imaging and clinical outcome, with a sensitivity of 100 per cent and a specificity of 91 per cent (Table [2](#bjs561-tbl-0002){ref-type="table"}). Phillips et al. [37](#bjs561-bib-0037){ref-type="ref"} reported a sensitivity of 100 per cent and a specificity of 70--90 per cent, compared with 90 and 30 per cent respectively for FA, and concluded that both modalities overpredicted areas of necrosis but that ICGA had higher predictive accuracy.

With the introduction of new software (SPY‐Q™ Analysis Toolkit; Novadaq, Toronto, Ontario, Canada) that enables more objective measurement of perfusion by assigning perfusion units to grey‐scale and colour images[40](#bjs561-bib-0040){ref-type="ref"}, studies have emerged that aimed to determine numerical threshold values that can be used to guide surgical resection. Perfusion values can be absolute or relative; absolute perfusion units (APUs) are based on the intensity of fluorescence at a given point compared with a standardized grey‐scale pixel brightness, and relative perfusion units (RPUs) are reported as a percentage of perfusion compared with a reference point that is selected by the user as an area of 100 per cent perfusion on a colourized image[38](#bjs561-bib-0038){ref-type="ref"} (Fig. [2](#bjs561-fig-0002){ref-type="fig"}). APU values also vary according to different generations of laser‐assisted ICGA equipment; Phillips and co‐workers[41](#bjs561-bib-0041){ref-type="ref"} found that an APU value of 3·7 on SPY^®^ 2001 (Novadaq, Bonita Springs, Florida, USA) equated to 23·8 on SPY^®^ Elite (Lifecell, Branchburg, New Jersey, USA) devices.

![Relative perfusion units on a colourized image generated by SPY‐Q™ software (courtesy of Novadaq Technologies; <http://novadaq.com/products/spy-elite/>)](BJS5-2-175-g003){#bjs561-fig-0002}

Five studies[19](#bjs561-bib-0019){ref-type="ref"} [20](#bjs561-bib-0020){ref-type="ref"}, [37](#bjs561-bib-0037){ref-type="ref"} [38](#bjs561-bib-0038){ref-type="ref"}, [40](#bjs561-bib-0040){ref-type="ref"} used SPY‐Q™ software to determine perfusion values to guide resection. There were divided opinions on whether absolute or relative perfusion units were more reliable. Phillips and colleagues[37](#bjs561-bib-0037){ref-type="ref"} advocated the use of APU as there was less variability between patients and the ability to extrapolate across patients. They reported that a perfusion unit threshold less than 3·7 was predictive of mastectomy flap necrosis, with 90 per cent sensitivity and 100 per cent specificity using the SPY^®^ 2001 device. Munabi *et al*.[19](#bjs561-bib-0019){ref-type="ref"} also used APU values to determine a threshold of less than 7 to predict necrosis (sensitivity 88 per cent, specificity 83 per cent) using the SPY^®^ Elite device. Interestingly, when they excluded patients who received adrenaline (epinephrine)‐containing tumescent solution or those with a history of smoking, a greater specificity was obtained at that perfusion level (96 per cent). Mattison and colleagues[38](#bjs561-bib-0038){ref-type="ref"} used contour levels to demarcate areas under chosen absolute values of 10, 15 and 20, and advised that the contour of 10 would provide the most acceptable results (sensitivity 100 per cent, specificity 68 per cent). All reported APU levels and associated predictive accuracy values are shown in *Table* [4](#bjs561-tbl-0004){ref-type="table"}, with recommended cut‐off values highlighted.

###### 

Absolute perfusion unit cut‐off value and associated predictive accuracy

  APU cut‐off value                            Sensitivity (%)   Specificity (%)                          Reference
  ------------------------------------------- ----------------- ----------------- ---------------------------------------------------------
  SPY^®^ Elite                                                                    
  20                                                 100               28          Mattison *et al*.[38](#bjs561-bib-0038){ref-type="ref"}
  15                                                 100               51          Mattison *et al*.[38](#bjs561-bib-0038){ref-type="ref"}
  13                                                 100               72           Munabi *et al*.[19](#bjs561-bib-0019){ref-type="ref"}
  10[\*](#bjs561-note-0012){ref-type="fn"}           100               68          Mattison *et al*.[38](#bjs561-bib-0038){ref-type="ref"}
  7[\*](#bjs561-note-0012){ref-type="fn"}            88                83           Munabi *et al*.[19](#bjs561-bib-0019){ref-type="ref"}
  6                                                  75                83           Munabi *et al*.[19](#bjs561-bib-0019){ref-type="ref"}
  3                                                  38                83           Munabi *et al* [19](#bjs561-bib-0019){ref-type="ref"}
  SPY^®^ 2001                                                                     
  8                                                  100               70          Phillips *et al*.[37](#bjs561-bib-0037){ref-type="ref"}
  3·7[\*](#bjs561-note-0012){ref-type="fn"}          100               90          Phillips *et al*.[37](#bjs561-bib-0037){ref-type="ref"}

APU, absolute perfusion unit.

Recommended values.

Two studies recommended use of relative perfusion values. Moyer and Losken[20](#bjs561-bib-0020){ref-type="ref"} found a RPU value of 25 per cent or less predicted non‐viable tissue 90 per cent of the time, whereas a value of 45 per cent or more predicted viable tissue 98 per cent of the time. Having a cut‐off value at 33 per cent gave a positive predictive value of 88 per cent and a negative predictive value of 16 per cent. Newman *et al*.[40](#bjs561-bib-0040){ref-type="ref"} reviewed 20 SPY^®^ images, ten of which had mastectomy flap necrosis and ten with adequate healing, to correlate absolute and relative values. They found that a mean APU value of 18·5 was not statistically significant in predicting necrosis (*P* = 0·068), but a mean RPU of 25·2 per cent was statistically significant (*P* \< 0·001). The authors concluded that the relative values gave more benefit, acting as an internal control for variances in patient factors. They recommended a relative value of 30 per cent or lower to be indicative of tissue ischaemia.

Secondary outcomes {#bjs561-sec-0017}
------------------

Two studies carried out a cost analysis for ICGA. Duggal and co‐workers[30](#bjs561-bib-0030){ref-type="ref"} performed a retrospective comparison of a cohort of patients undergoing SSM and immediate reconstruction assessed using ICGA with a demographically matched historical cohort evaluated using clinical judgement. When clinical judgement was used, the total cost of complications resulting in unexpected reoperation was calculated at US \$417 576·27 (€336 950·64; exchange rate 6 March 2018). This was compared with the total cost of complications and cost of equipment for ICGA, which was calculated to be \$304 562·62 (€245 757·67), resulting in a total cost‐saving of \$113 013·65 (€91 192·97), or \$614 (€495·45) per patient. In contrast, Kanuri *et al*.[42](#bjs561-bib-0042){ref-type="ref"} claimed that an extra cost of US \$1537·30 (€1240·48) would be incurred for every case of necrosis prevented if ICGA were used in all immediate reconstruction procedures. They went on to suggest that selective use in patients at high risk of skin flap necrosis would be an alternative and more cost‐effective approach. No cost analysis was performed for FA; however, a hand‐held Wood\'s lamp is reported to cost approximately US \$300 (€242), with each vial of 10 per cent fluorescein costing less than \$15 (€12)[33](#bjs561-bib-0033){ref-type="ref"}.

Two studies recorded adverse reactions to ICGA or FA[7](#bjs561-bib-0007){ref-type="ref"} [33](#bjs561-bib-0033){ref-type="ref"}. One severe allergic reaction to FA was reported[33](#bjs561-bib-0033){ref-type="ref"}.

Discussion {#bjs561-sec-0018}
==========

Mastectomy flap necrosis is a common complication of SSM and immediate reconstruction that can result in significant morbidity, which may be reduced by intraoperative imaging. However, the value of intraoperative technology does not lie in its ability to confirm a clinically obvious outcome, but in its ability to predict a course that is not suspected, uncertain or contrary to clinical judgement[20](#bjs561-bib-0020){ref-type="ref"}. Not only should the technique correctly predict areas of poor perfusion, but it should be able to distinguish between poorly perfused tissue that will survive and tissue that is destined for necrosis in a quantitative manner, so that the user should not need to rely on subjective parameters. Other factors to consider include ease of administration, operator dependency, side‐effect profile and cost when considering adoption of intraoperative techniques in the clinical setting.

Two main modalities were identified in this study: FA and ICGA. Fluorescein dye was first used by Ehrlich[43](#bjs561-bib-0043){ref-type="ref"} to assess fluid in the anterior chamber of the eye. It has since been applied in various medical situations to determine vascular perfusion of tissue[44](#bjs561-bib-0044){ref-type="ref"}. Its value in assessing skin flap viability was first described by Myers[45](#bjs561-bib-0045){ref-type="ref"}, who used it to predict and prevent skin slough after mastectomy. Singer *et al*.[46](#bjs561-bib-0046){ref-type="ref"} then used it to assess mastectomy skin flap viability in immediate breast reconstructions. When injected intravenously it accumulates in the extracellular compartment and emits a yellow--green fluorescence on exposure to ultraviolet light, indicating adequate (yellow) or poor (blue) perfusion[37](#bjs561-bib-0037){ref-type="ref"} [47](#bjs561-bib-0047){ref-type="ref"}. Advantages of this technique are that it is readily accessible and affordable; however, the slow rate of action and long half‐life of fluorescein make it impractical for repeated imaging in the intraoperative setting[7](#bjs561-bib-0007){ref-type="ref"}, and the qualitative nature of the data is subject to interobserver variability. Although its use has led to a decrease in mean mastectomy flap necrosis compared with clinical judgement[33](#bjs561-bib-0033){ref-type="ref"}, the ambiguity in intermediate areas of fluorescence has the tendency to lead the operator to underpredict mastectomy flap survival, resulting in the resection of viable tissue[37](#bjs561-bib-0037){ref-type="ref"} [39](#bjs561-bib-0039){ref-type="ref"}. Quantification of tissue fluorescein content by means of fibre‐optic dermofluorometry has been attempted in order to define numerical thresholds for skin flap viability[48](#bjs561-bib-0048){ref-type="ref"}, [49](#bjs561-bib-0049){ref-type="ref"}, [50](#bjs561-bib-0050){ref-type="ref"}, [51](#bjs561-bib-0051){ref-type="ref"}; however, it has not been implemented further in the monitoring of mastectomy skin flaps. There is also a steep learning curve associated with use of a Wood\'s lamp[24](#bjs561-bib-0024){ref-type="ref"}, and side‐effects ranging from urticarial to anaphylactic reactions have been reported[33](#bjs561-bib-0033){ref-type="ref"} [52](#bjs561-bib-0052){ref-type="ref"}.

The lack of sufficient objectivity of data that FA offers for intermediately perfused skin flaps renders it useful solely for identifying clearly viable tissue, which may also be adequately assessed by clinical judgement. This and the physiological limitations of fluorescein dye, which make it inferior to ICG, a second‐generation dye, may explain why it has not been adopted widely for use in the plastic and reconstructive setting for assessment of mastectomy skin flaps[53](#bjs561-bib-0053){ref-type="ref"}.

ICGA can be used for real‐time imaging of tissue perfusion. First used by Kogure and colleagues[54](#bjs561-bib-0054){ref-type="ref"} to visualize choroidal veins, it is now used to evaluate blood flow in a range of specialties including cardiology, hepatology and ophthalmology[24](#bjs561-bib-0024){ref-type="ref"}. When ICG is injected, it binds to the plasma proteins and remains in the intravascular compartment. It emits fluorescence when excited by infrared light, to demonstrate perfusion in the dermis and superficial soft tissues to a depth of 3·6 mm, which is deeper than the superficial plexus shown by FA[55](#bjs561-bib-0055){ref-type="ref"}. Advantages of ICG compared with fluorescein include the faster rate of action that allows quicker imaging, and the added benefit of a shorter half‐life (2·5 min), which allows multiple images to be captured in a short space of time. It also has a superior side‐effect profile[24](#bjs561-bib-0024){ref-type="ref"} [56](#bjs561-bib-0056){ref-type="ref"}.

The use of ICGA to evaluate mastectomy flap viability has also resulted in a decrease in mean mastectomy flap necrosis and reoperation rates (*Table* [3](#bjs561-tbl-0003){ref-type="table"}). With the introduction of quantitative software there is the potential for more accurate designation of numerical thresholds to guide tissue resection, but at present there is still a tendency for overprediction of necrosis[37](#bjs561-bib-0037){ref-type="ref"}. Intravascular imaging can also be affected by any source of regional vasoconstriction secondary to operative technique (such as use of adrenaline‐containing tumescent solution) or patient factors (for example smoking)[26](#bjs561-bib-0026){ref-type="ref"}. This was reflected in the higher incidence of false‐positives found in such populations by Munabi and colleagues[19](#bjs561-bib-0019){ref-type="ref"}. Moyer and Losken[20](#bjs561-bib-0020){ref-type="ref"} noted that smokers tended to require a greater percentage of perfusion (5 per cent higher) to sustain viable tissue compared with non‐smokers (*P* = 0·243). On the contrary, among patients with a history of hypertension and those with African American skin types flap tissue remained viable at a lower mean perfusion score (*P* = 0·117 and *P* = 0·015 respectively). These factors will require consideration when attributing perfusion thresholds as well as accounting for the variability resulting from the concentration of ICG dye, operating room temperature, mean arterial BP, systemic vascular resistance, ambient room light and interdevice variability[40](#bjs561-bib-0040){ref-type="ref"}.

Alternative methods that have been suggested for use in predicting skin flap viability include heat‐measuring devices such as a thermometer, hydrogen electrodes, laser and colour Doppler instruments, and probes measuring tissue oxygen saturation, carbon dioxide and pH[39](#bjs561-bib-0039){ref-type="ref"}. None of these has translated into the intraoperative setting, although ODIS (tissue oximetry) was used in a small pilot study[34](#bjs561-bib-0034){ref-type="ref"} to measure the ratio of oxyhaemoglobin to deoxyhaemoglobin to evaluate perfusion in five patients. One of these patients developed mastectomy flap necrosis that required reoperation. Although the authors concluded that this was a potential method for skin flap evaluation, no further study of this technique has been undertaken. Laser Doppler flowmetry has been used to evaluate the nipple--areola complex after subcutaneous reduction mammaplasties and subcutaneous mastectomies, but it did not accurately predict necrosis in all patients who experienced skin slough[57](#bjs561-bib-0057){ref-type="ref"}. These techniques are used more commonly in the postoperative setting to monitor the anastomotic patency of free flaps, either by external and implantable Doppler monitoring or laser Doppler flowmetry[58](#bjs561-bib-0058){ref-type="ref"}.

There was a lack of homogeneity in the reporting of mastectomy necrosis. This was echoed by Lemaine *et al*.[59](#bjs561-bib-0059){ref-type="ref"}, who highlighted the lack of a standardized definition of mastectomy flap necrosis or consistency between studies, ranging from binary classifications to subjective grading systems. They suggested a scoring system (skin ischaemia necrosis (SKIN) score) which takes into account both the depth and surface area involved, and correlates the score with the need for reoperation. This may be a potentially useful tool in reporting necrosis rates, providing a means of better communication and understanding of outcomes.

Similarly, there was an inconsistency in reporting complications, and not all studies were clear in defining the reason for reoperation. As inadequate skin flap perfusion may contribute to other seemingly unrelated complications, such as delayed wound healing and infection[22](#bjs561-bib-0022){ref-type="ref"}, consistent and systematic reporting of infection, seroma and delayed wound healing should be carried out, along with the severity of reoperation undertaken as a result of skin flap necrosis (such as simple debridement, readjustment of reconstruction or implant removal). To facilitate cost analysis, there should be reporting of prolonged hospital stay, duration of prolonged wound care owing to complications, and prolonged time to completion of breast reconstruction resulting from mastectomy flap necrosis.

This review is limited in that references of included papers were not reviewed and grey literature searches were not undertaken. The included studies were assigned a LOE adapted from the Oxford Centre for Evidence‐Based Medicine, but no other assessment of scientific quality was undertaken.

Currently, intraoperative evaluation of mastectomy flaps using ICGA provides better predictive accuracy than FA and clinical judgement, leading to reduced rates of mastectomy flap necrosis. However, owing to its tendency to overpredict areas of necrosis, leading to potential loss of viable tissue and a negative impact on reconstructive options, there is a need to establish reliable numerical thresholds to guide surgical resection. There is heterogeneity in current studies regarding the device and software being used, and a lack of consensus on whether absolute or relative perfusion should be used as the reference unit. Appropriately powered prospective studies should be set up to evaluate predictive accuracies using standardized operating protocols and patient inclusion and exclusion criteria.

It has been suggested that intraoperative modalities should be used selectively for patients at high risk of mastectomy flap necrosis to facilitate cost‐effectiveness[42](#bjs561-bib-0042){ref-type="ref"}. Patients with pigmentation or skin discolouration that poses a challenge for clinical judgement may also benefit from use of intraoperative imaging modalities[26](#bjs561-bib-0026){ref-type="ref"}.

Supporting information
======================

###### 

**Table S1** Boolean Literature Search Strategy \[MEDLINE\]

**Table S2** Boolean Literature Search Strategy \[EMBASE\]

###### 

Click here for additional data file.

D.G. and A.M. are joint senior authors of this article.

*Disclosure*: The authors declare no conflict of interest.
